Clinical Trials Logo

Pancreatic Cancer Resectable clinical trials

View clinical trials related to Pancreatic Cancer Resectable.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06375928 Not yet recruiting - Clinical trials for Biliary Tract Neoplasms

EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to evaluate temporal delay (days) between biliary drainage (EUS-CDS vs ERCP as first line therapy) and surgery in patients with resectable distal malignant biliary obstruction.

NCT ID: NCT06368063 Not yet recruiting - Clinical trials for Pancreatic Cancer Resectable

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

Start date: April 2024
Phase: Phase 4
Study type: Interventional

The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer

NCT ID: NCT06287749 Not yet recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Start date: March 1, 2024
Phase:
Study type: Observational

The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project

NCT ID: NCT05637567 Not yet recruiting - Clinical trials for Pancreatic Cancer Resectable

Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head

ASAP
Start date: April 2024
Phase: Phase 2
Study type: Interventional

This randomized, controlled clinical trial compares the perioperative treatment with acetylsalicylic acid (aspirin) in patients with cancer of the pancreatic head. The main question it aims to answer is: Do patients treated perioperatively with aspirin develop less metastasis after curative resection of pancreatic head tumors? Participants will be asked to : - take a daily aspirin tablet starting 1-4 weeks before surgery until 6 months after surgery - participate in regular follow-up visits.

NCT ID: NCT05479708 Not yet recruiting - Clinical trials for Pancreatic Cancer Resectable

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

Start date: August 2022
Phase:
Study type: Observational

Short-term relapse and poor survival are prevalent in patients with pancreatic adenocarcinoma (PAAD) after surgeries. Despite the importance of adjuvant treatments for resected PAAD patients, there is currently no suitable biomarker to identify those individuals with high risk of recurrence and inform therapeutic decision making. In this study, we aim to examine whether postoperative circulating tumor DNA (ctDNA) could be used as a biomarker for early detection of minimal residual disease (MRD) and predicting relapse in resected PAAD through high-depth targeted next-generation sequencing.